These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 29618565)

  • 21. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.
    Dorman SE; Goldberg S; Stout JE; Muzanyi G; Johnson JL; Weiner M; Bozeman L; Heilig CM; Feng PJ; Moro R; Narita M; Nahid P; Ray S; Bates E; Haile B; Nuermberger EL; Vernon A; Schluger NW;
    J Infect Dis; 2012 Oct; 206(7):1030-40. PubMed ID: 22850121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages.
    Dhillon J; Mitchison DA
    Am Rev Respir Dis; 1992 Jan; 145(1):212-4. PubMed ID: 1309967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages.
    Mor N; Simon B; Mezo N; Heifets L
    Antimicrob Agents Chemother; 1995 Sep; 39(9):2073-7. PubMed ID: 8540718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and Target Attainment of SQ109 in Plasma and Human-Like Tuberculosis Lesions in Rabbits.
    Egbelowo O; Sarathy JP; Gausi K; Zimmerman MD; Wang H; Wijnant GJ; Kaya F; Gengenbacher M; Van N; Degefu Y; Nacy C; Aldridge BB; Carter CL; Denti P; Dartois V
    Antimicrob Agents Chemother; 2021 Aug; 65(9):e0002421. PubMed ID: 34228540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine.
    Zvada SP; Denti P; Geldenhuys H; Meredith S; van As D; Hatherill M; Hanekom W; Wiesner L; Simonsson US; Jindani A; Harrison T; McIlleron HM
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4471-3. PubMed ID: 22585223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rifapentine--a long-acting rifamycin for tuberculosis.
    Med Lett Drugs Ther; 1999 Feb; 41(1047):21-2. PubMed ID: 10076594
    [No Abstract]   [Full Text] [Related]  

  • 27. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
    Rosenthal IM; Williams K; Tyagi S; Peloquin CA; Vernon AA; Bishai WR; Grosset JH; Nuermberger EL
    Am J Respir Crit Care Med; 2006 Jul; 174(1):94-101. PubMed ID: 16574936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
    Conde MB; Mello FC; Duarte RS; Cavalcante SC; Rolla V; Dalcolmo M; Loredo C; Durovni B; Armstrong DT; Efron A; Barnes GL; Marzinke MA; Savic RM; Dooley KE; Cohn S; Moulton LH; Chaisson RE; Dorman SE
    PLoS One; 2016; 11(5):e0154778. PubMed ID: 27159505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection.
    Phaisal W; Albitar O; Chariyavilaskul P; Jantarabenjakul W; Wacharachaisurapol N; Ghadzi SMS; Zainal H; Harun SN
    J Antimicrob Chemother; 2024 Jun; 79(6):1270-1278. PubMed ID: 38661209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro evaluation of novel inhalable dry powders consisting of thioridazine and rifapentine for rapid tuberculosis treatment.
    Parumasivam T; Chan JG; Pang A; Quan DH; Triccas JA; Britton WJ; Chan HK
    Eur J Pharm Biopharm; 2016 Oct; 107():205-14. PubMed ID: 27422209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment-Shortening Effect of a Novel Regimen Combining Clofazimine and High-Dose Rifapentine in Pathologically Distinct Mouse Models of Tuberculosis.
    Saini V; Ammerman NC; Chang YS; Tasneen R; Chaisson RE; Jain S; Nuermberger E; Grosset JH
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30936097
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts.
    Schechter M; Zajdenverg R; Falco G; Barnes GL; Faulhaber JC; Coberly JS; Moore RD; Chaisson RE
    Am J Respir Crit Care Med; 2006 Apr; 173(8):922-6. PubMed ID: 16474028
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rifapentine Population Pharmacokinetics and Dosing Recommendations for Latent Tuberculosis Infection.
    Hibma JE; Radtke KK; Dorman SE; Jindani A; Dooley KE; Weiner M; McIlleron HM; Savic RM
    Am J Respir Crit Care Med; 2020 Sep; 202(6):866-877. PubMed ID: 32412342
    [No Abstract]   [Full Text] [Related]  

  • 34. In Vitro Evaluation of Inhalable Verapamil-Rifapentine Particles for Tuberculosis Therapy.
    Parumasivam T; Chan JG; Pang A; Quan DH; Triccas JA; Britton WJ; Chan HK
    Mol Pharm; 2016 Mar; 13(3):979-89. PubMed ID: 26808409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Xpert MTB/RIF Assay Shows Faster Clearance of Mycobacterium tuberculosis DNA with Higher Levels of Rifapentine Exposure.
    Jayakumar A; Savic RM; Everett CK; Benator D; Alland D; Heilig CM; Weiner M; Friedrich SO; Martinson NA; Kerrigan A; Zamudio C; Goldberg SV; Whitworth WC; Davis JL; Nahid P
    J Clin Microbiol; 2016 Dec; 54(12):3028-3033. PubMed ID: 27733634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tuberculosis: current treatment, diagnostics, and newer antitubercular agents in clinical trials.
    Ahsan MJ; Ansari MY; Yasmin S; Jadav SS; Kumar P; Garg SK; Aseri A; Khalilullah H
    Infect Disord Drug Targets; 2015; 15(1):32-41. PubMed ID: 25246035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and pharmacological hallmarks of rifapentine's use in diabetes patients with active and latent tuberculosis: do we know enough?
    Zheng C; Hu X; Zhao L; Hu M; Gao F
    Drug Des Devel Ther; 2017; 11():2957-2968. PubMed ID: 29066867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study.
    Keung AC; Owens RC; Eller MG; Weir SJ; Nicolau DP; Nightingale CH
    Antimicrob Agents Chemother; 1999 May; 43(5):1230-3. PubMed ID: 10223941
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.
    Dorman SE; Savic RM; Goldberg S; Stout JE; Schluger N; Muzanyi G; Johnson JL; Nahid P; Hecker EJ; Heilig CM; Bozeman L; Feng PJ; Moro RN; MacKenzie W; Dooley KE; Nuermberger EL; Vernon A; Weiner M;
    Am J Respir Crit Care Med; 2015 Feb; 191(3):333-43. PubMed ID: 25489785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug.
    Svensson EM; Murray S; Karlsson MO; Dooley KE
    J Antimicrob Chemother; 2015 Apr; 70(4):1106-14. PubMed ID: 25535219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.